SPL-707

SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC 50 of 77 nM for hSPPL2a. SPL-707 inhibits γ-secretase ( IC 50 =6.1 μM) and SPP ( IC 50 =3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells In Vitro SPL-707 (Compound 40) inhibits mouse SPPL2a (IC 50 =0.18 μM), rat SPPL2a (IC 50 =0.056 μM) and human SPPL2a (IC 50 =0.16 μM), human SPPL2b (IC 50 =0.43 μM) by a high content imaging assay (HCA). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SPL-707 (Compound 40; 3-30 mg/kg; orally; b.i.d.; for 11 days) leads to a reduction in B cells and myeloid dendritic cells without affecting γ-secretase activity . SPL-707 (3 mg/kg of po and 1 mg/kg of iv) has a CL of 6 mL/min•kg, and an AUC of 8787 h•nM . SPL-707 (1, 3 mg/kg; b.i.d.; first dose at 0 h, second dose at 8 h) achieves full inhibition of CD74/p8 processing in spleen in female Lewis rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice with 5-12 weeks of age Dosage: 3, 10, and 30 mg/kg Administration: Orally; b.i.d. (with 8 and 16 h dosing intervals); for 11 days Result: Led to a reduction in B cells and myeloid dendritic cells without affecting γ-secretase activity. Animal Model: Female Sprague−Dawley rat Dosage: 3 mg/kg of po and 1 mg/kg of iv (Pharmacokinetic Analysis) Administration: PO or IV Result: Had a CL of 6 mL/min•kg, and an AUC of 8787 h•nM. Form:Solid IC50& Target:IC50: 77 nM (SPPL2a), 6.1 μM (γ-secretase) and 3.7 μM (SPP)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet